Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anti-microRNA-219 locked nucleic acid
- Development stage
- Unknown
- Lead developer
- Exiqon
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous, Intrathecal
01
Overview
Anti-microRNA-219 locked nucleic acid (anti-miR-219 LNA) is a synthetic locked nucleic acid (LNA) modified antisense oligonucleotide designed to inhibit microRNA-219 (miR-219 / miR-219a-5p). By complementary binding to mature miR-219, it blocks its silencing activity. In preclinical research, anti-miR-219 LNA has been utilized to study the role of miR-219 in various pathological processes, including renal fibrosis (where it preserves ALDH1L2 expression and suppresses fibronectin accumulation) and NMDA receptor-mediated neurobehavioral dysfunction.
- Other names
- LNA-anti-miR-219LNA-anti-miR219LNA-anti-miR 219LNA-antimiR-219LNA-antimiR219LNA-antimiR 219anti-miR-219 LNAanti-miR219 LNAanti-miR 219 LNAanti-miR-219 locked nucleic acidanti-miR219 locked nucleic acidanti-miR 219 locked nucleic acidanti-mir-219a-5p LNAanti-mir219a-5p LNAanti-mir 219a-5p LNA
02
Targets
miR-219 (MicroRNA-219)
Beyond the preview
Go deeper on anti-microRNA-219 locked nucleic acid.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anti-microRNA-219 locked nucleic acid.